Skip to main content
. 2023 Aug 22;29(21):4341–4351. doi: 10.1158/1078-0432.CCR-23-0257

Figure 2.

Figure 2. Best overall response depicted by the percentage of change in target lesion size relative to baseline and by dose level in 18 patients with measurable disease. Of the 21 patients treated, one patient was not evaluated for radiologic response due to early clinical progression, one patient had non-measurable but evaluable disease, and one patient had a different imaging modality post-baseline for determining progression. Conc, concomitant; E, Ewing sarcoma; N, neuroblastoma; R, rhabdomyosarcoma; Seq, sequential; VI, vincristine and irinotecan; W, Wilms tumor.

Best overall response depicted by the percentage of change in target lesion size relative to baseline and by dose level in 18 patients with measurable disease. Of the 21 patients treated, one patient was not evaluated for radiologic response due to early clinical progression, one patient had non-measurable but evaluable disease, and one patient had a different imaging modality post-baseline for determining progression. Conc, concomitant; E, Ewing sarcoma; N, neuroblastoma; R, rhabdomyosarcoma; Seq, sequential; VI, vincristine and irinotecan; W, Wilms tumor.